🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Congrats Naomi Haas and team for the 5 yr update on ph3 Keynote-564 in #kidneycancer 👉 Ab#4514 ASCO #ASCO25 👉bit.ly/44KiA7o👉Benefits w/ adjuvant pembro over placebo maintained (DFS HR 0.71 & OS HR 0.66)👇Toni Choueiri, MD Tom Powles OncoAlert UroToday.com KidneyCAN

Hard to describe how big of a moment that was! Congrats Dr Renee Maria Saliby for a brilliant ASCO presentation! You make us all proud! And kudos to the whole team behind this work Marc Machaalani Carolina Alves Costa Silva, MD, PhD. It truly takes a village!

🗣️Kidney Cancer Oral Abstracts #ASCO25 👉Abs4505: Dr Robert Motzer MD presenting 9⃣yr f/u Nivo/Ipi vs Sunitinib for 1L ccRCC #CheckMate214 ITT (n = 1096) ♦️96 mo PFS rate = (23% vs 9%) ♦️96 mo DOR rate = (48% vs 19%) ♦️108 mo OS rate = (31% vs 20%) ♦️mOS (53mo vs 38mo) (HR 0.71)

With all the amazing presentations at #ASCO25, just wanted to take a moment to share some of our data related to #biomarkers from the #IMmotion010 phase III study, a trial of adjuvant #atezolizumab vs pbo. A tremendous team helped me put this together, including Wenxin (Vincent) Xu

At ASCO #ASCO25 #abs4506 Toni Choueiri, MD delivers another terrific talk 👉Results from Ph 1 ARC-20 study #kidneycancer👉Casdatifan (novel HIF-2a inhibitor) plus cabozantinib in previously treated mRCC👇promising activity, ph3 started OncoAlert UroToday.com @KidneyCAN Kidney Cancer

🗣️Kidney Cancer Oral Abstracts #ASCO25 👉Abs4507: Dr Vivek Narayan presenting 5⃣yr follow up of #Belzutifan for VHL-associated neoplasms #LITESPARK004 n = 61 🧬germline VHL alteration ≥1 measurable nonmetastatic RCC tumor no tumor > 3 cm req surgery no prior systemic

🗣️Kidney Cancer Oral Abstracts #ASCO25 👉Abs4508: Dr #SamerSrour presenting #ALLO316 (🎯anti-CD70 CAR-T) in refractory ccRCC #TRAVERSE n = 44 median of 3 prior therapies (1-8) CD70 positive ccRCC = 36/44 (82%) ⏲️ median f/u = 6.8 mo (0.8-39.5) 💉(LD) w/ fludara + cyclop ±

🗣️Kidney Cancer Oral Abstracts #ASCO25 👉Dr Tian Zhang, MD, MHS given outstanding summary "From Established Therapies to Emerging Innovations in Renal Cell Carcinoma: Checkpoints, Oxygen, and T Cells" ❓How do we build on the success of 1L ICI-based doublets #CM214? 👉 Biomarker

Incredible lecture from SWOG Cancer Research Network’s own Dr. Dawn Herschman, someone who truly does patient-centered care, regarding PROs: All treatments are tolerable when you don’t ask patients how they feel. SO TRUE! #ASCO25 #patientoutcomes #cancercare

As a stage IV cancer survivor, I can’t begin to tell you how humbling it is to spend National Cancer Survivors Day at #ASCO25. “Pictures worth a thousand words” was my first thought as I looked back on photos from the day. Two years ago I attended #ASCO for the very first time,

She was prolific (& continues to be!) w many presentations & publications. Shown below is her on stage at KidneyCAN's #KCRS21 meeting, where she delivered an oral presentation alongside Alex Chehrazi-Raffle, MD Nick Salgia & Nazli Dizman ... as a premed! Wow! (3/6)

The term "rising star" gets thrown about quite a bit, but our money is certainly on Jasnoor Malhotra 🤩 She is a changemaker!

This is what inaction looks like. Promising trials paused. Researchers leaving the field. Progress stalled. Underfunding cancer research has real consequences, for patients and for science. Read more: bit.ly/ThisAmericanLi… cbsn.ws/3Hk0KhN #RestoreTheResearch

Stellar presentation ASCO #ASCO25 by trailblazer Rana McKay, MD, FASCO on ETCTN trial with radium +|- olaparib in mCRPC #prostatecancer 👉rPFS ⬆️ with the combo w/wo HRRm👇Data continues to reinforce role of PARPi in rationale combinations Toni Choueiri, MD (mentor), UroToday.com OncoAlert

Want to catch up on #ASCO25 Kidney Cancer updates? Join ecancer roundtable in Renal cell Carcinoma: ecancer.org/en/video/12406… cc: ASCO Michael Serzan, MD Guillermo de Velasco

#WorldKidneyCancerDay is June 19! This year’s theme is Show Your Kidneys Some Love, and that starts with three simple tests. These help monitor kidney function and guide next steps in care. For more information🔗 bit.ly/WCKD_2025 #AcceleratingCures

Looking forward to #MACancerLobbyDay at the State House next Tuesday. Standing alongside other advocates, we will look to expand access to Biomarker Testing & Eliminate Barriers for Patients to receive Patient Navigation Services ACSCAN Massachusetts Dana-Farber Lank Center for Genitourinary Oncology Toni Choueiri, MD

Research cuts don’t just stall studies, they drive talent away. This is brain drain, and it’s one of the hidden costs of cutting CDMRP funding. We can’t afford to lose the people working toward better treatments. #RestoreTheResearch #AcceleratingCures

Just diagnosed with #KidneyCancer? The medical terms can feel overwhelming at first, but understanding the language of your diagnosis is an important step in advocating for yourself. Explore more in our Patient Resource Center: kidneycan.org #AcceleratingCures

KidneyCAN recently met with Rep. Cuellar (TX) to advocate for the restoration of CDMRP funding. These conversations are so important to protecting progress in #KidneyCancer science and making sure patients have access to better treatments. #RestoreTheResearch #AcceleratingCures